沙库巴曲缬沙坦与依那普利治疗恰加斯病所致心力衰竭:一项开放标签、多中心随机临床试验
中位随访25.2个月,分层胜率为1.52(95%CI 1.28-1.82;P<.001),但心血管死亡和心力衰竭住院无显著差异,沙库巴曲缬沙坦组12周NT-proBNP降幅更大。
要点
- 在恰加斯病所致射血分数降低的心力衰竭患者中,沙库巴曲缬沙坦与依那普利的临床结局无显著差异。
- 沙库巴曲缬沙坦组12周NT-proBNP中位降幅30.6%,依那普利组为5.5%。
- 分层胜比为1.52(95%CI 1.28-1.82;P<.001),利于沙库巴曲缬沙坦。
核心结论
- 在恰加斯病所致射血分数降低的心力衰竭患者中,沙库巴曲缬沙坦与依那普利在临床结局方面无显著差异,但沙库巴曲缬沙坦组12周NT-proBNP降幅更大。
研究设计与样本
- 开放标签、多中心随机临床试验,于2019年12月10日至2023年9月13日在阿根廷、巴西、哥伦比亚和墨西哥的83个中心筛查患者。
- 纳入心力衰竭、确诊恰加斯病、左心室射血分数40%或以下,且NT-proBNP≥600 pg/mL(或BNP≥150 pg/mL)或若过去12个月内因心力衰竭住院则NT-proBNP≥400 pg/mL(或BNP≥100 pg/mL)的患者。
- 462例随机分配至沙库巴曲缬沙坦组(目标剂量200 mg每日两次),460例分配至依那普利组(目标剂量10 mg每日两次),均在标准治疗基础上给药。
- 主要终点为分层复合终点,依次检验心血管原因死亡、心力衰竭住院或12周时NT-proBNP较基线的相对变化,采用胜率法分析。
- 统计分析于2025年5月至7月进行。
主要发现
- 中位(IQR)随访25.2(18.4-33.2)个月,沙库巴曲缬沙坦组心血管死亡110例(23.8%[分层比较中18.3%胜出]),依那普利组117例(25.4%[17.5%胜出])。
- 沙库巴曲缬沙坦组102例(22.1%[7.7%胜出])发生首次心力衰竭住院,依那普利组111例(24.1%[6.9%胜出])。
- 沙库巴曲缬沙坦组12周NT-proBNP中位(IQR)降幅为30.6%(-54.3%至-0.9%),贡献22.5%胜出;依那普利组降幅为5.5%(-31.9%至37.5%),贡献7.2%胜出。
- 沙库巴曲缬沙坦对比依那普利的分层胜比为1.52(95%CI 1.28-1.82;P<.001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The efficacy and safety of guideline-recommended treatments for heart failure (HF) are uncertain in patients with Chagas disease. OBJECTIVE: To evaluate the efficacy and safety of the angiotensin receptor-neprilysin inhibitor sacubitril/valsartan in patients with HF with reduced ejection fraction due to Chagas disease. DESIGN, SETTING, AND PARTICIPANTS: From December 10, 2019, through September 13, 2023, patients with HF, confirmed diagnosis of Chagas disease, left ventricular ejection fraction of 40% or less, and N-terminal pro-B-type natriuretic peptide (NT-proBNP) of 600 pg/mL or greater (or B-type natriuretic peptide [BNP] ≥150 pg/mL) or 400 pg/mL or greater (or BNP ≥100 pg/mL) if hospitalized for HF within the previous 12 months were screened at 83 sites in Argentina, Brazil, Colombia, and Mexico. Statistical analysis was conducted between May and July 2025. INTERVENTIONS: Patients were randomized to receive sacubitril/valsartan (target dose, 200 mg twice daily) or enalapril (target dose, 10 mg twice daily), in addition to standard therapy. MAIN OUTCOMES AND MEASURES: The primary end point was a hierarchical composite outcome tested, in order, of death from cardiovascular causes, hospitalization for HF, or relative change in NT-proBNP from baseline to 12 weeks. The primary analysis was done using a win ratio approach. RESULTS: Overall, 462 participants were randomized to receive sacubitril/valsartan and 460 to receive enalapril (mean [SD] age, 64.2 [10.8] years; 387 [42.0%] were female). Over a median (IQR) follow-up of 25.2 (18.4-33.2) months, cardiovascular death occurred in 110 patients (23.8% [18.3% wins in the hierarchical comparison]) in the sacubitril/valsartan group and 117 patients (25.4% [17.5% wins]) in the enalapril group. A total of 102 patients (22.1% [7.7% wins]) in the sacubitril/valsartan group and 111 (24.1% [6.9% wins]) in the enalapril group experienced a first hospitalization for HF. Patients in the sacubitril/valsartan group had a median (IQR) decrease in NT-proBNP of 30.6% (-54.3% to -0.9%) at 12 weeks, leading to 22.5% wins, while those in the enalapril group had a 5.5% (-31.9% to 37.5%) decrease (7.2% wins). The resulting stratified win ratio was 1.52 (95% CI, 1.28-1.82; P < .001) for sacubitril/valsartan compared with enalapril. CONCLUSIONS AND RELEVANCE: In patients with HF with reduced ejection fraction due to Chagas disease, there was no significant difference in clinical outcomes between sacubitril/valsartan and enalapril, but there was a greater reduction in NT-proBNP at 12 weeks in patients in the sacubitril/valsartan group. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04023227.
引用
- Lopes RD, Bocchi EA, Echeverría LE, et al. Sacubitril/Valsartan vs Enalapril in Heart Failure Due to Chagas Disease: An Open-Label, Multicenter Randomized Clinical Trial. JAMA. 2026. PMID: 41335448. doi:10.1001/jama.2025.19808
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。